133 related articles for article (PubMed ID: 10029438)
1. Immunohistochemical evaluation of K-ras, p53, and HER-2/neu expression in hyperplastic, dysplastic, and carcinomatous lesions of the pancreas: evidence for multistep carcinogenesis.
Apple SK; Hecht JR; Lewin DN; Jahromi SA; Grody WW; Nieberg RK
Hum Pathol; 1999 Feb; 30(2):123-9. PubMed ID: 10029438
[TBL] [Abstract][Full Text] [Related]
2. Expression of Ki-67, p53, and K-ras in chronic pancreatitis and pancreatic ductal adenocarcinoma.
Jeong S; Lee DH; Lee JI; Lee JW; Kwon KS; Kim PS; Kim HG; Shin YW; Kim YS; Kim YB
World J Gastroenterol; 2005 Nov; 11(43):6765-9. PubMed ID: 16425381
[TBL] [Abstract][Full Text] [Related]
3. Amplification and overexpression of HER-2/neu in invasive ductal carcinomas of the pancreas and pancreatic intraepithelial neoplasms and the relationship to the expression of p21(WAF1/CIP1).
Hermanová M; Lukás Z; Nenutil R; Brázdil J; Kroupová I; Kren L; Pazourková M; Růzicka M; Díte P
Neoplasma; 2004; 51(2):77-83. PubMed ID: 15190415
[TBL] [Abstract][Full Text] [Related]
4. Ductal lesions in patients with chronic pancreatitis show K-ras mutations in a frequency similar to that in the normal pancreas and lack nuclear immunoreactivity for p53.
Lüttges J; Diederichs A; Menke MA; Vogel I; Kremer B; Klöppel G
Cancer; 2000 Jun; 88(11):2495-504. PubMed ID: 10861425
[TBL] [Abstract][Full Text] [Related]
5. [Morphologic, morphometric and immunohistochemical studies on pancreatic intraductal hyperplasia and infiltrating carcinoma].
Tomaszewska R
Folia Med Cracov; 1999; 40(1-2):101-41. PubMed ID: 10909469
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms.
Day JD; Digiuseppe JA; Yeo C; Lai-Goldman M; Anderson SM; Goodman SN; Kern SE; Hruban RH
Hum Pathol; 1996 Feb; 27(2):119-24. PubMed ID: 8617452
[TBL] [Abstract][Full Text] [Related]
7. Relationship of family cancer history to the expression of p53, p21WAF-1, HER-2/neu, and K-ras mutation in pancreatic adenocarcinoma.
Dergham ST; Dugan MC; Arlauskas P; Du W; Vaitkevicius VK; Crissman JD; Sarkar FH
Int J Pancreatol; 1997 Jun; 21(3):225-34. PubMed ID: 9322121
[TBL] [Abstract][Full Text] [Related]
8. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia.
Caldas C; Hahn SA; Hruban RH; Redston MS; Yeo CJ; Kern SE
Cancer Res; 1994 Jul; 54(13):3568-73. PubMed ID: 8012983
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical study of genetic alterations in intraductal and invasive ductal tumors of the pancreas.
Islam HK; Fujioka Y; Tomidokoro T; Sugiura H; Takahashi T; Kondo S; Katoh H
Hepatogastroenterology; 2001; 48(39):879-83. PubMed ID: 11462947
[TBL] [Abstract][Full Text] [Related]
10. The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium.
Lüttges J; Schlehe B; Menke MA; Vogel I; Henne-Bruns D; Klöppel G
Cancer; 1999 Apr; 85(8):1703-10. PubMed ID: 10223563
[TBL] [Abstract][Full Text] [Related]
11. An immunostaining panel for diagnosis of malignancy in mucinous tumors of the pancreas.
Zhao J; Liang SX; Savas L; Banner BF
Arch Pathol Lab Med; 2001 Jun; 125(6):765-9. PubMed ID: 11371228
[TBL] [Abstract][Full Text] [Related]
12. [Topoisomerase IIalpha and HER2/neu gene alterations and their correlation in pancreatic ductal adenocarcinomas].
Liang ZY; Wang WZ; Gao J; Wu SF; Zeng X; Liu TH
Zhonghua Bing Li Xue Za Zhi; 2007 Feb; 36(2):102-6. PubMed ID: 17493384
[TBL] [Abstract][Full Text] [Related]
13. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma.
Kawesha A; Ghaneh P; Andrén-Sandberg A; Ograed D; Skar R; Dawiskiba S; Evans JD; Campbell F; Lemoine N; Neoptolemos JP
Int J Cancer; 2000 Nov; 89(6):469-74. PubMed ID: 11102889
[TBL] [Abstract][Full Text] [Related]
14. Expression of cyclooxygenase-2 in breast carcinogenesis and its relation to HER-2/neu and p53 protein expression in invasive ductal carcinoma.
Cho MH; Yoon JH; Jaegal YJ; Choi YD; Lee JS; Lee JH; Nam JH; Choi C; Lee MC; Park CS; Woo Juhng S; Min KW
Breast; 2006 Jun; 15(3):390-8. PubMed ID: 16169726
[TBL] [Abstract][Full Text] [Related]
15. Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression in pancreatic carcinoma.
Koka V; Potti A; Koch M; Fraiman G; Mehdi S; Levitt R
Anticancer Res; 2002; 22(3):1593-7. PubMed ID: 12168842
[TBL] [Abstract][Full Text] [Related]
16. In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis.
Qian J; Niu J; Li M; Chiao PJ; Tsao MS
Cancer Res; 2005 Jun; 65(12):5045-53. PubMed ID: 15958547
[TBL] [Abstract][Full Text] [Related]
17. Expression of cathepsin E in pancreas: a possible tumor marker for pancreas, a preliminary report.
Azuma T; Hirai M; Ito S; Yamamoto K; Taggart RT; Matsuba T; Yasukawa K; Uno K; Hayakumo T; Nakajima M
Int J Cancer; 1996 Aug; 67(4):492-7. PubMed ID: 8759606
[TBL] [Abstract][Full Text] [Related]
18. Bcl-2 expression in pancreas development and pancreatic cancer progression.
Campani D; Esposito I; Boggi U; Cecchetti D; Menicagli M; De Negri F; Colizzi L; Del Chiaro M; Mosca F; Fornaciari G; Bevilacqua G
J Pathol; 2001 Aug; 194(4):444-50. PubMed ID: 11523052
[TBL] [Abstract][Full Text] [Related]
19. Expression of p53 protein in precursor lesions and adenocarcinoma of human pancreas.
Boschman CR; Stryker S; Reddy JK; Rao MS
Am J Pathol; 1994 Dec; 145(6):1291-5. PubMed ID: 7992834
[TBL] [Abstract][Full Text] [Related]
20. Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas.
Bongiorno PF; Whyte RI; Lesser EJ; Moore JH; Orringer MB; Beer DG
J Thorac Cardiovasc Surg; 1994 Feb; 107(2):590-5. PubMed ID: 7905543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
